|
Jun 3
|
Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday
|
|
Jun 2
|
Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment
|
|
Jun 2
|
Corcept Therapeutics Says Relacorilant Met Primary Endpoint in Phase 3 Ovarian Cancer Trial
|
|
Jun 2
|
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
|
|
Jun 2
|
1 Cash-Heavy Stock on Our Watchlist and 2 to Steer Clear Of
|
|
May 29
|
New Strong Sell Stocks for May 29th
|
|
May 23
|
Discover 3 Growth Stocks With Insider Ownership Up To 28%
|
|
May 22
|
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)
|
|
May 19
|
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed
|
|
Mar 28
|
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?
|
|
Mar 26
|
3 Reasons to Sell CORT and 1 Stock to Buy Instead
|
|
Mar 21
|
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 19
|
3 Growth Stocks in Hot Water
|
|
Mar 14
|
1 Small-Cap Stock on Our Buy List and 2 to Avoid
|
|
Mar 11
|
Top Growth Companies With Significant Insider Ownership
|
|
Mar 10
|
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
|
|
Mar 7
|
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
|
|
Mar 7
|
Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?
|
|
Feb 12
|
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
|
|
Dec 31
|
Corcept Submits Application for Another Cushing's Syndrome Drug
|